Debbie Rigby takes a look at the latest in research news
Analysis of Australia GP prescribing data shows metformin is frequently prescribed at a dose not consistent with current Australian Diabetes Society (ADS) guidelines for dosing in renal impairment, followed by DPP4 inhibitors and sulphonylureas. The drug classes with the highest proportion of prescriptions with dosage not consistent with ADS guidelines were SGLT2 inhibitors (83%), followed by biguanides (58%) and DPP4 inhibitors (46%).
BMC Family Practice 2019;20:29.
The effect of a residential care pharmacist on medication administration practices in aged care
This pilot study has demonstrated the inclusion of a pharmacist in RACHs can reduce rates of inappropriate DFM and staff time spent on medication rounds, and improve documentation rates of allergies, ADRs and medication‐related incidents. A residential care pharmacist position was implemented at the study site for six months, with a focus on performing medication reviews and quality improvement activities.
Journal of Clinical Pharmacy and Therapeutics, first published 21 February 2019.
A Cochrane review did not find consistent evidence that H1 AH treatments are effective as ‘add‐on’ therapy for eczema when compared to placebo. Fexofenadine probably leads to a small improvement in patient‐assessed pruritus, with probably no significant difference in the amount of treatment used to prevent eczema flares.
Cochrane Database of Systematic Reviews 2019, Issue 1.
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to confer benefits in diabetic patients with heart failure, cardiovascular disease, and renal disease. This drug class has also been associated with major adverse events, including diabetic ketoacidosis in type 1 diabetes patients and limb amputations and genital and urinary tract infections in type 2 diabetes patients.
US Pharm. 2019;44(2):HS9-HS12.